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Phorbol esters, tctradecanoylphorbolacetate, sapintoxin-A, 1%deoxyphorbol-phenylacctate, I2-dcoxyphorbol-phenylacetate-20_acctate, thyrnelea- 
toxin and resinifcratoxin were investigated for their abilities to activate the PKC-isotypes a, b,, y, 6 and E. PKC-isotypes were grouped into two 
classes on the basis of Ca” requirements for activation by phorbol esters; 01, /3,, and y being Ca a+-dependent forms and S and E being Ca2+-indepcn- 
dent. PKC-isotype selective activation by phorbol esters was observed in that SAPA failed to activate PKC-S up to a concentration of 1000 ngml-’ 
and DOPPA only activated PKC-/?, over the same range of concentrations. 
Protein kinase C, Isotype ~1, &, y, 6 and E; Phorbol ester; Daphnane ester; Selective activation; Cat+ requirement 
1. INTRODUCTION 
The major tumour-promoting phorbol-ester (TPA) 
receptor has been identified as the Ca2+- and PS- 
dependent kinase, PKC, by purification to homogenei- 
ty from brain tissue [l-3]. The phorbol ester range of 
natural plant products is known to contain a number of 
chemically related substances [4] but the property of 
tumour promotion is rigidly structurally controlled 
[5-g]. Although biologically active, few of these 
derivatives are promoting agents in Berenblum tests on 
mouse skin. For example, TPA the most commonly 
used member of the phorbol family of compounds has 
a number of biological effects, whilst other derivatives 
have a more restricted spectrum of action [9] but have 
been shown to activate PKC and inhibit [3H]phorbol- 
debutyrate binding [IO]. Pharmacological analysis [9] 
of the actions of phorbol esters indicates receptor 
heterogeneity and Scatchard analysis has produced 
plots from binding experiments in chick embryo cells 
consistent with more than one class of binding site [l 11. 
These analyses may in part be explained by the fact 
that PKC is now known to exist as a number of isotypes 
Abbreviations: TPA, tetradecanoylphorbolacetate; SAPA, Fapin- 
toxin A, 12-O-t-methylaminobenzoyl-13-O-acetyl-4-deoxyphorbol; 
DOPP, 12-deoxyphorbol-13-0-phenylacetate; DOPPA, 12-deoxy- 
phorbol-13-0-phenylacetate-20-acetate; TX, thymeleatoxin, 9,13,14- 
orthobenzoyl-6-7, epoxy-resinferonol-12-0-cinnamate; Rx, resinifer- 
atoxin, 9,13,14-orfhophenylacetyl-resiniferonol-20-O~homovanillate; 
PKC, protein kinase C; PS, phosphatidylserine; DAG, diacylglycerol 
The (Y. 81, and y subtypes of PKC were prepared from bovine brain 
by the method of Marais and Parker [16]. PKC-6 was isolated from 
COS-1 cells transfected with bovine plasmid DNA vectors for PKC 
according to A.R. Olivier and P.J. Parker (unpublished). PKC-t was 
expressed and purified as described previously [17,18]. All purified 
isotypes were immunologically pure and were stored at - 20°C in 2 
mM EDTA, 0.02% Triton X-100,20 mM fris-HCI, 50% glycerol and 
1 mM DTT in concentrated form until required for use. TPA was pur- 
chased from Sigma, UK. Thymeleatoxin (TX) was isolated from the 
leaves of Thymelea birsutu [19], Sapintoxin A (SAPA) from the ripe 
fruits of Supium indicum 1201, It-deoxyphorbol-13-phenylacetate 
(DOP), 12-deoxyphorbol-13-phenylacetate-20-acetate (DOPA) and 
resiniferatoxin (Rx) were isolated from the fresh latex of Euphorbiu 
poissonii and Euphorbia unispina [21]. Pure phorbol esters were 
stored as 1 mg/ml solutions in redistilled acetone under Nz gas at 
-4°C until required for the assays. 
2.2. Protein kinase C assays 
Corresponde!rce address: F.J, Evans, Department of Pharmacog- individual isotypes of PKC were diluted with buffer (2 mM EDTA, 
nosy, The School of Pharmacy, 29-39 Brunswick Square, London 0.02% Triton X-100, 20 mM Tris-HCI, and 1 mM DTT at pH 7.5) to 
WCIN IAX, UK give an activity in the range of 1-4 units (nmol/min/ml) of kinase ac- 
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which may be variously distributed in tissues. The 
isotypes Q, fl and y were originally defined with the re- 
quirements of Ca” and PS for activation [12,13]. 
Subsequently, the isotypes 6, e and t were described [14] 
and more recently the q-subtype has been defined fl5]. 
In this communication six phorbol-related esters of dif- 
ferent biological activities have been compared for their 
abilities tc activate PKC isotypes cz, PI, y, 6 and e. The 
co-factor requirements with regard to Cat+ for activa- 
tion by these phorbol esters was also assessed in an at- 
tempt to further explain the pronounced differences 
observed in the actions of structurally related phorbol 
esters. 
2. MATERIALS AND METHODS 
2.1, Protein kinase C isorypes and phorbol esters 
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tivity and with a suitable adjustment o a final concentration of 10% 
glycerol immediately before use. The assay for kinase activity was 
prepared by mixing 20 ~1 of the substrate mix (IGO m&M HEPES. 1 
mM EGTA, 25 mM MgClz and either 2.5 mg.ml-’ histone 111s 
(Sigma. UK) or with 1 mg*ml-’ of synthetic peptide substrated for 6 
and c- isotypes of PKC [18]. 10 al of the micelle mix (PS lipid products) 
5 mg*ml-‘, phorbol ester dried under NZ and reconstituted with Tris- 
HCI 2 mM. 1% v/v Triton X-100 at pH 7.5 and 5 pl of enzyme. The 
assay commenced with the addition of 5 pl of the ATP mix (1 mM 
ATP, 500000 cpm/assay [r*P]ATP (Amersham, UK) to give a final 
concentration in the PKC assay of HEPES buffer 50 mM, ATP 125 
PM, [“P]ATP 500000 cpm, MgClz, 10 mM, CaClz 0.756 mM, free 
calcium 100 pM, EGTA 0.5 mM, EDTA 0.25 mM. DlT 0.125 mM, 
Triton X-100 2.5 mg.ml-‘, PS 1.25 mg.ml-‘, histone 1.25 mgmml- 
or synthetic substrates 0.25 mg*ml-’ at pH 7.5 with various concen- 
trations of phorbol ester in a total volume of 40 pl. The assay was ter- 
minated by spotting a 25 pl aliquot onto ion-exchange paper and 
washing three times in 30% acetic acid for 10 min on each occasion. 
Radioactivity of the ion-exchange paper strips was counted in plas:ic 
vials by Cherenkov counting using a Packard Tri-carb L.S. spec- 
trometer mode 3255. 
3. RESULTS AND DISCUSSON 
The phorbol esters used in these experiments (Fig. I) 
were shown to have various abilities to activate ibc 
PKC-isotypes (Y, 6, y, 6 and e as demonstrated in Fig. 2. 
The isotypes PKC-!: and PKC-q were not available for 
use in these experiments. Kinase activation assays were 
carried out up to a maximum concentration of 1000 
ng* ml-‘. This was considered to be the highest concen- 
tration of relevance to in vivo systems where phorbol 
ester responses are measured. Furthermore, our 
previous work concerning brain ‘pool’ PKC activation 
and binding [l l] using phorbol esters of different 
biological activities, suggested that biologically active 
phorbols could be classified into three groups. Firstly, 
a group of highly potent TPA-like derivatives fully ac- 
tivated PKC with ACse values of 100 ng vml-’ or less, a 
second group of compounds that were only able to in- 
duce about 30% of the maximum activation induced by 
TPA and the last group which only activated PKC at 
high concentrations (SO00 ng * ml- ‘). Our present results 
using pure PKC-isotypes also show compounds with a 
type three activation pattern on certain isotypes. This 
effect can be seen in Fig. 2C (iv) where at low concen- 
trations DOPPA fails to activate PKC-7 but al concen- 
trations in excess of 1000 ng*ml-’ a significant activa- 
tion is induced. SeveraI explanations may account for 
this ‘late’ or high dose activation but it is likely that this 
is a non-specific effect. Phorbol esters are amphipatic 
molecules and at high concentrations ina micellar assay 
mix could produce surfactant effects. This activation 
may have little relevance to a physiological/phar- 
macological situation where such a high concentration 
may not occur in situ. 
Although PKC was initially described as a Ca2+- and 
PS-dependent lcinase [22j, the currently known isotypes 
are believed to have varying CaZC requirements for ac- 
tivation. From our results ccncerning PKC activation 
by phorbol esters it was possibIe to separate the PKC- 
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Fig. 1. The structures of the phorbol derivatives used in PKC activa- 
tion assays as described under Fig. 2. (i) TPA, tetradecanoylphor- 
bolacetate; (ii) SAPA, Sapintoxin A; (iii) DOP, 12-deoxyphorbol- 
l3-phenylacetate; (iv) DOPPA, 12-deoxy-phorbol-l3-phenylacetate- 
20-acetate; (v) TX, Thymeleatoxin; (iv) Rx, Resiniferatoxin. 
isotypes into the Ca” -dependent a,,~?, and y group and 
the Ca2+-independent forms 6 and E. The effects of the 
presence or absence of 100 @I Cat’ upon the activation 
of PKC-o(, -fir, and -y are shown in Fig. 2A,B,C. For 
activation of these kinases by TPA (i), SAPA (ii), 
DOPP (iii) and TX (v) there is a clear shift to the left in 
the activation curve in the presence of 100 PM Ca2+. In 
the absence of Ca2+ an increase in phorbol ester concen- 
tration of up to 1000 ng *ml- ’ was required to achieve 
a 50% maximal response with PKC-(Y and PKC-y (Fig. 
2A,C). A similar but less marked effect was also ob- 
served for PKC-/31 (Fig. 2B). Of the three 
Ca2+-dependent PKC-isotypes, PI may be marginally 
less Ca2’-dependent than CY and y. 
The activation pattern of PKC-6 and -E in the 
presence and absence of Ca2+ was clearly distinct from 
that of PKC-(r, $31 and -7. These kinases were potently 
activated by TPA and DOPP to a similar level in the 
presence or absence of Ca2+ (Fig. 2D (i)(ii), 2E (i)(ii)). 
These results may reflect the Ca2+ dependencies for ac- 
tivation per se of the PKC-isotypes available to us but 
they merely reflect co-factor requirements for activa- 
tion of particuiar isuiri;tr, of PKC by different phorbol 
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Fig. 2. Activation of the isotypes of PKC. cy. 01, y, d and t by the phorbol derivatives TPA, SAPA, DOP, DOPPA, Tx and Rx. Kinasc activation 
assays were carried out by the method of Harmon et al. [31] as modified in section 2.2. The results are expressed as percent maximal activation 
produced by TPA vs concentration of phorbol ester ~~g.iill-’ up to a maximum of 1000 ngeml-‘, (o)+Ca”, 100 FM; (0) - Ca*‘. A: activation 
of the PKC-isotypc cr; B: activation of the PKC-isotype 0,; C: activation of the PKC-isotype y; D: activation of the PKC-isotype 6; E: activation 
of the PKC-isotype E. Activation in all cases induced by (ij TPA; (ii) SAPA; (iii) DOP; (iv) DOPPA; (v) TX; (Vl) Rx as from Fig. 1. 
derivatives. The phorbol esters are increasingly used as of activating PKC-isotypes in an in vitro assay to bet- 
pharmacological/biochemical probes in cellular ween 60 and 75% of maximal activation in the absence 
systems 191 often to predict the physiological functions of added Ca’+. In the presence of added Cat+, satura- 
of PKC. It is of interest o note from our results that tion occurs at a lower TPA concentration and c1e-W 
VA, a broad-spectrum phorbol ester probe, is capable the Cat+ binding region of PKC does affect its ability to 
7 
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activate, enhancing efficiency; but Ca*+ is not essential 
for activation by TPA. 
The phorbol esters used here were selected for dif- 
ferences in their recorded biological effects. TPA is a 
colrrplete turnour-promoting agent f5], induces Iym- 
phocyte mitogenesis [23], HL-60 cell differentiation 
[24], platelet aggregation 1251 and skin inflammation 
amongst other effects. Two compounds have more 
restricted biological effects. DOPP and SAPA are non- 
promoting in Berenblum experiments [26] but are 
highly potent PKC activators [lo]. They appear to be 
more potent than TPA in the activation of the (Y and 01 
PKC-isotypes. From Fig. 2A, TPA can be seen to ex- 
hibit an activation concentration 50% (AGO) of 80 
ng. ml-’ for PKC-cu activation whilst SAPA has an 
A& of 12.5 ngeml-’ and DOPP of only 5.0 ngeml-‘. 
A similar effect is seen with PKC-/31 (Fig. 2B). The 
daphnane, TX, is a second-stage promoting agent [26] 
but it has an activation pattern for PKC-isotypes CY, /31 
and y similar to that of SAPA although it is generally 
much less potent. It is also of interest o note that the 
activation of PKC-(r, $1 and -y by DOPP, SAPA and 
TX is More Ca2+-dependent than for TPA. The com- 
pounds were considerably less potent in their activation 
of the Ca’+-independent isotypes 6 and E (Fig. 213,E). 
TPA and DOPP were similar in their abilities to ac- 
tivate these isotypes whilst DOPPA and TX were unable 
to induce activation in concentrations up to 1000 
ngmml’r. It is possible that the highly potent but non- 
promoting SAPA may prove to be a valuable tool for 
the positive control of TPA to examine 6-PKC effects in 
cellular systems. 
It has been suggested from structure-activity studies 
[5-g] and computer imaging [27] that the C-20 hydroxy 
group of the phorbols is important for activity (Fig. 1). 
Two derivatives were used in this study which exhibit an 
acyl group at this position. Rx is an ortho-ester related 
to TX and although it is not a tumour promoter it is the 
most potent pro-inflammatory agent of the group [28]. 
This compound has previously been shown to induce a 
Ce*‘-inhibited kinase activity from lymphocytes and 
Macrophages [29,30]. DOPPA is the C-20 acetate of 
DO1’P and is the most limited in its spectrum of effect 
[9] of the six phorbols used (Figure 1). DOPA failed to 
activate PKC-isotypes (Y, y, 6 or E up to concentrations 
of 1000 ng-ml-‘. However, in the presence of 100 pM 
Cat+ DOPPA was shown to activate PKC-/3r at 100 
ng-ml-r to about 50% of maximal activation produced 
by TPA (Fig. 2B(iv)). DOPPA may prove to be a useful 
phorbo! derivative for the examination of the role of 
PKC-/3r , Rx very weakly activated PKC-fir and .y in the 
presence of Ca’+ but failed to activate PKC-cu, -S or -e 
(Fig. 2). These C-20 acyl derivatives have previously 
been shown to inhibit [3H]phorbol-dibutyrate binding 
[lo] and have now been shown to have significant 
resticted abilities to activate PKC-isotypes. 
The six phorbol esters of different biological ac- 
8 
tivitics have exhibited different abilities to activate 
PKC-isotypes available to us and certain phsrbol esters 
appear to have both selective actions and different Ca2+ 
requirements for activation of the isotypes. These 
results may in part help to explain the supposed phorbol 
ester receptor heterogeneity as predicted from phar- 
macological and binding analysis. 
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